Allergy Shots for Dust Mite Allergy: The Strongest Perennial Evidence

Yes, dust mite allergy shots are among the most evidence-supported forms of allergen immunotherapy available. The Calderon Cochrane Review on HDM SCIT (2010) reported symptom standardized mean difference of -0.95 and medication SMD of -1.88 — effect sizes larger than most other allergens in the immunotherapy evidence base. Long-term data from Rodriguez-Plata et al. (2023) found 55% of HDM SCIT patients asymptomatic at 10-year post-treatment follow-up. Both Dermatophagoides pteronyssinus (Der p 1) and D. farinae (Der f 1) are included in US dust mite extract formulations, covering the two most clinically relevant HDM species. Clinical remission rates in Korean HDM SCIT cohorts reached 76.6% at a mean of 4.9 years of treatment.

The recommended maintenance dose for dust mite SCIT targets Der p 1 content of 7-12 mcg and Der f 1 content of approximately 10 mcg per 0.5 mL injection, as specified in the AAAAI/ACAAI Practice Parameter (Cox et al., 2011, Box 8). In standardized product terms, this corresponds to maintenance doses of approximately 500-2,000 Allergy Units (AU) per injection for commercially standardized HDM extracts. Reaching and sustaining this dose for 3+ years is the key determinant of long-term efficacy. Sub-therapeutic dosing — a common issue in real-world practice — is one of the primary reasons for suboptimal SCIT responses. Your allergist should target the specific major allergen content range when preparing your treatment vials.

Most patients with dust mite allergy notice meaningful symptom improvement within 6-12 months of starting treatment, typically after reaching the maintenance dose. Because HDM exposure is perennial rather than seasonal, patients often track improvement against baseline year-round symptoms rather than a distinct allergy season. Early improvements in morning nasal congestion, sleep quality, and eye symptoms are often the first reported benefits. Full disease-modifying benefit requires completing the minimum 3-year treatment course — short courses of 1-2 years have not demonstrated post-treatment durability in controlled trials (Scadding et al., JAMA 2017 GRASS trial). Patients who are HDM-monosensitized and treated for 3+ years show the best long-term outcomes.

Yes, particularly for HDM-monosensitized asthmatic patients. The overall SCIT asthma evidence base shows consistent symptom and medication reductions (SMD -0.59 and -1.21 respectively, Cochrane 2010) but no consistent FEV1 improvement. However, the HDM-monosensitized asthma subgroup in Zheng et al.'s 2023 pediatric meta-analysis showed FEV1 improvement of +5.37% predicted — a clinically meaningful lung function gain not seen in polysensitized or mixed-allergen asthma populations. GINA 2024 guidelines endorse HDM SLIT as an add-on therapy for HDM-sensitized allergic rhinitis patients with comorbid asthma when FEV1 exceeds 70% predicted. Uncontrolled asthma (FEV1 <70%) remains a contraindication for initiating SCIT.

For house dust mite specifically, SCIT appears to have a slight efficacy advantage over SLIT based on network meta-analysis evidence. Nelson et al.'s 2021 network meta-analysis found SCIT produced the largest symptom score effect among all HDM treatment modalities and statistically outperformed both SLIT drops (SMD difference 0.461) and SLIT tablets (SMD difference 0.329). However, this advantage is modest, and SLIT has substantially better safety (zero confirmed fatalities worldwide vs. SCIT's rare but real anaphylaxis risk) and dramatically greater convenience (daily drops at home vs. weekly then biweekly clinic visits). The choice between HDM SCIT and SLIT should be individualized based on patient preference, adherence likelihood, allergen profile, and comorbid conditions.